{"query":"briumvi.com","mode":"domain","best":{"domain":"briumvi.com","status":"valid","tier":"listed","authority":52,"verified":false,"title":"BRIUMVI® (ublituximab-xiiy)","summary":"BRIUMVI (ublituximab-xiiy) is a CD20-directed monoclonal antibody from TG Therapeutics, FDA-approved in December 2022 for relapsing forms of multiple sclerosis (RMS). It is administered as a 1-hour intravenous infusion twice per year, following the starting dose. This is the official patient site. See Important Safety Information and full Prescribing Information for complete details.","country":null,"country_source":"cdn","publisher_country":null,"publisher_country_source":null,"hosting_country":null,"llms_txt":"https://briumvi.com/llms.txt","llms_full_txt":null,"last_checked":"2026-10-20T01:35:31.216Z","agent_terms":null,"categories":["healthcare"],"capabilities":[],"inferred_tags":["ublituximab","multiple sclerosis","relapsing ms","cd20 therapy","prescribing information"],"audience":"consumers","agent_uses":["read_docs"],"language":"en","platform_generated":false,"agent_summary":"Official patient site for BRIUMVI (ublituximab-xiiy), an FDA-approved IV therapy for relapsing multiple sclerosis, with dosing, safety and efficacy information.","llms_txt_cached":"https://agentwebmap.com/v1/domain/briumvi.com/llms.txt","agentic":"documentation","section_keys":["about-briumvi","optional","patient-stories","patient-support","treatment-experience"],"section_partial":false,"section_indexed_at":"2026-10-21T14:05:45.989Z","why":["authority 52 (listed)","checked 4953 minutes ago"]},"read":{"llms_txt":"https://briumvi.com/llms.txt","llms_full_txt":null,"nested_llms_txt":[]},"terms":null,"health":{"ok":true,"status":"valid","tier":"listed","authority":52,"last_checked":"2026-10-20T01:35:31.216Z","checked_minutes_ago":4953,"stale":true,"max_age_seconds":86400,"live_checked":false,"http_status":200,"last_valid":"2026-10-20T01:35:31.216Z","content_hash":"745e45c167845da2edc38f0e1a46a94d"},"sources":[],"match":{"strength":"domain","reason":"Exact domain or its registered publisher."},"provenance":{"selection":"directory","verification":"domain_ownership","terms":"unknown","excerpts":"publisher_link_metadata","health":"stored_crawl"},"alternatives":[]}